The Study of Ω-NaBen, a Novel Crystalline Form of Sodium Benzoate, Has Been Published in CNS & Neurological Disorders - Drug Targets, Indicating Its Superior Physicochemical Properties, Central Nervous System…

SyneuRx Discovers Pentarlandir® Ultrapure Tannic Acid as a Potential Treatment for Influenza Virus Infection Press Release September 18, 2024 New Taipei City, Taiwan – September 18, 2024 –A groundbreaking study…

SyneuRx International (Taiwan) Corp. Discover a Well-built D-cycloserine Formulation for CNS Disorders Press Release April 26, 2024 New Taipei City, Taiwan – April 26, 2024 –SyneuRx International (TPEX:6575), a biotech…

SyneuRx International (Taiwan) Corp. Discovers Potential Drug DGDX for Treating Mental Disorders and Neurodegenerative Disorders Press Release April 12, 2024 New Taipei City, Taiwan – April 12, 2024 – SyneuRx…

SyneuRx CEO Emil Tsai Publishes a Research Article in The Lancet Regional Health - Western Pacific, Indicating a Sharp Increase in Suicide Attempts During the COVID-19 Pandemic in French Polynesia…

SyneuRx CEO Emil Tsai Named Fellow of National Academy of Inventors Renowned Johns Hopkins and Harvard-educated neuroscience and brain disorder expert is being inducted as a 2022 fellow from prestigious…

SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® Positive results show Pentarlandir is safe and effective in patients with mild-to-moderate COVID-19 Press Release…

Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board Renowned neuroscientist known for his groundbreaking discoveries in psychiatric disorders joins advisory board to drive clinical development efforts Press…

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01) Early research suggests Pentarlandir is safe to use against COVID-19; Phase 3 trial evaluating…

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants Acting as Both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir® is…